Zymeworks Inc. (ZYME)
NASDAQ · Manufacturing · Pharmaceutical preparations
$26.52−$0.2900 (−1.08%) on the dayAs of the close; data may be delayed.
ZYME price, last 12 months
Key stats
- Previous close
- $26.81
- Open
- $26.50
- Day range
- $26.23 – $26.90
- 52-week range
- $15.81 – $31.34
- Volume
- 474.5K
- Avg volume (20 days)
- 677.7K
- Market cap
- $1.9B
Performance
1W−0.2%
1M−9.5%
3M+9.8%
6M+7.4%
YTD+0.7%
1Y+62.7%
vs S&P 500, 1Y+45.9 pts
Technicals and fundamentals
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.9B